» Articles » PMID: 16398622

Non-melanoma Skin Cancer in Australia: the 2002 National Survey and Trends Since 1985

Overview
Journal Med J Aust
Specialty General Medicine
Date 2006 Jan 10
PMID 16398622
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To measure the incidence of treated non-melanoma skin cancer (NMSC) in Australia in 2002 and investigate trends since 1985 by histological type, sex, age group, latitude and skin type.

Design: Face-to-face survey between 1 January and 31 December 2002 using stratified sampling of households to identify people treated for skin cancer in the previous 12 months. Self-reported diagnoses were confirmed with treatment providers. Data from similar surveys conducted in 1985, 1990 and 1995 were used to assess trends.

Setting: Whole of Australia (population 19.6 million).

Participants: Of 57 215 people interviewed, 4098 said they had been treated for skin cancer in the past year and 3198 gave permission for their diagnoses to be confirmed with their doctor.

Results: 817 people were confirmed as having at least one skin cancer treated in the past year. The age-standardised rate per 100 000 population for NMSC was 1170, for basal cell carcinoma (BCC) 884, and for squamous cell carcinoma (SCC) 387. The estimated number of NMSC cases in Australia for 2002 was 374 000. Cumulative risks to age 70 years of having at least one NMSC were 70% for men and 58% for women. Rates of BCC and SCC have increased since 1985, and the increases greatest for people aged 60 years and older; rates for those younger than 60 years have stabilised.

Conclusions: The incidence of treated NMSC in Australia in 2002 was more than five times the incidence of all other cancers combined. Although the overall NMSC rates have risen since 1985, the stabilisation of rates for people younger than 60 years who were exposed to skin cancer prevention programs in their youth highlights the importance of maintaining and strengthening these programs.

Citing Articles

Ultraviolet and infrared radiation in Australia: assessing the benefits, risks, and optimal exposure guidelines.

Sharma K, Dixon K, Munch G, Chang D, Zhou X Front Public Health. 2025; 12():1505904.

PMID: 39744344 PMC: 11688272. DOI: 10.3389/fpubh.2024.1505904.


Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.

Sol S, Boncimino F, Todorova K, Waszyn S, Mandinova A Int J Mol Sci. 2024; 25(13).

PMID: 39000164 PMC: 11241167. DOI: 10.3390/ijms25137056.


Quality measures in primary care skin cancer management: a qualitative study of the views of key informants.

Spanos S, Singh N, Laginha B, Arnolda G, Smith A, Wilkinson D BMJ Open. 2024; 14(7):e080670.

PMID: 38991668 PMC: 11243125. DOI: 10.1136/bmjopen-2023-080670.


Molecular Profiling and the Interaction of Somatic Mutations with Transcriptomic Profiles in Non-Melanoma Skin Cancer (NMSC) in a Population Exposed to Arsenic.

Jasmine F, Argos M, Khamkevych Y, Islam T, Rakibuz-Zaman M, Shahriar M Cells. 2024; 13(12.

PMID: 38920684 PMC: 11201393. DOI: 10.3390/cells13121056.


Photodynamic Therapy for the Treatment of Basal Cell Carcinoma: A Comprehensive Review of Randomized Controlled Trials.

Koumprentziotis I, Rompoti N, Liopyris K, Nicolaidou E, Stratigos A Dermatol Pract Concept. 2024; 14(2).

PMID: 38810046 PMC: 11136039. DOI: 10.5826/dpc.1402a105.